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NeuropathologyHuntington disease (HD) is an inherited, fatal neurodegenerative disease with no disease-modifying therapy
currently available. In addition to characteristic motor deﬁcits and atrophy of the caudate nucleus, signature
hallmarks of HD include behavioral abnormalities, immune activation, and cortical and white matter loss. The
identiﬁcation and validation of novel therapeutic targets that contribute to these degenerative cellular processes
may lead to new interventions that slow or even halt the course of this insidious disease. Semaphorin 4D
(SEMA4D) is a transmembrane signaling molecule that modulates a variety of processes central to neuroinﬂam-
mation and neurodegeneration including glial cell activation, neuronal growth cone collapse and apoptosis of
neural precursors, as well as inhibition of oligodendrocyte migration, differentiation and process formation.
Therefore, inhibition of SEMA4D signaling could reduce CNS inﬂammation, increase neuronal outgrowth and
enhance oligodendrocyte maturation, which may be of therapeutic beneﬁt in the treatment of several neurode-
generative diseases, including HD. To that end, we evaluated the preclinical therapeutic efﬁcacy of an anti-
SEMA4D monoclonal antibody, which prevents the interaction between SEMA4D and its receptors, in the
YAC128 transgenicHDmousemodel. Anti-SEMA4D treatment ameliorated neuropathological signatures, includ-
ing striatal atrophy, cortical atrophy, and corpus callosum atrophy and prevented testicular degeneration in
YAC128 mice. In parallel, a subset of behavioral symptoms was improved in anti-SEMA4D treated YAC128
mice, including reduced anxiety-like behavior and rescue of cognitive deﬁcits. There was, however, no discern-
ible effect on motor deﬁcits. The preservation of brain gray and white matter and improvement in behavioral
measures in YAC128 mice treated with anti-SEMA4D suggest that this approach could represent a viable
therapeutic strategy for the treatment of HD. Importantly, this work provides in vivo demonstration that
inhibition of pathways initiated by SEMA4D constitutes a novel approach to moderation of neurodegeneration.
© 2015 Elsevier Inc. All rights reserved.Introduction
Semaphorins are a family of transmembrane proteins that inﬂuence
a range of processes related to health and disease, including theP-32, dopamine- and cAMP-
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ect.com).development and regeneration of the central nervous (CNS) and cardio-
vascular systems (Hota and Buck, 2012), as well as physiologic and
pathologic immune responses (Suzuki et al., 2008). In the CNS,
semaphorin 4D (SEMA4D), a class IV semaphorin, is expressed on inﬁl-
trating immune cells and oligodendrocyte precursor cells and its recep-
tors are expressed on neurons, oligodendrocytes, astrocytes and
endothelial cells (Okuno et al., 2010) and unpublished observations.
SEMA4D has been shown to serve as an axonal guidance molecule
(Swiercz et al., 2002) aswell asmediating GABAergic and glutamatergic
synapse development (Paradis et al., 2007) among other activities. In
the periphery, the highest expression of SEMA4D is observed on T
cells and less abundantly on B cells, macrophages and dendritic cells
47A.L. Southwell et al. / Neurobiology of Disease 76 (2015) 46–56where expression is signiﬁcantly upregulated upon cellular activation
(Bougeret et al., 1992; Shi et al., 2000). SEMA4D has been reported to
play a role in immune cell activation andmigration (Suzuki et al., 2008).
The SEMA4D protein consists of a short cytoplasmic tail, transmem-
brane domain and extracellular Ig and Sema domains (Furuyama et al.,
1996;Hall et al., 1996; Shi et al., 2000) and acts on three known receptors,
Plexin-B1, Plexin-B2 and CD72 (Suzuki et al., 2008). Both membrane-
associated SEMA4D as well as an extracellular soluble fragment, which
results from cleavage of the protein by membrane metalloproteases
between the transmembrane and Ig domains, are biologically active
(Elhabazi et al., 2001; Zhu et al., 2007).
In addition to axonal guidance and synapse formation (Kuzirian
et al., 2013; Raissi et al., 2013), SEMA4D has been shown to play a
role in migration and differentiation of neuronal and oligodendro-
cyte precursor cells, CNS inﬂammation and neurodegeneration. For
example, SEMA4D deﬁciency leads to increased oligodendrocyte dif-
ferentiation, whereas exogenously added soluble SEMA4D inhibits
oligodendrocyte differentiation (Yamaguchi et al., 2012). Interest-
ingly, SEMA4D expression is increased in the cerebrospinal ﬂuid of
patients with human T-lymphotropic virus 1-associated myelopathy
in which T cell-derived SEMA4D induces collapse of process exten-
sion of immature oligodendrocytes and death of immature neural
cells, resulting in compromised remyelination of the inﬂamed brain
(Giraudon et al., 2004). Further, SEMA4D-deﬁcient mice are resistant
to the development of experimental autoimmune encephalomyelitis
(EAE) (Kumanogoh et al., 2000), and blockade of SEMA4D signiﬁ-
cantly inhibits microglial activation and neuroinﬂammation in EAE
(Okuno et al., 2010). Similarly, SEMA4D stimulation of endothelial
cells leads to production of the pro-inﬂammatory cytokine IL-8
(Yang et al., 2011). These observations implicate SEMA4D as playing
a role in potentiating CNS inﬂammation and neurodegeneration and
suggest that SEMA4D is a potential therapeutic target for treatment
of neurodegenerative diseases.
A high afﬁnity neutralizing antibody to SEMA4D, mAb67-2, has
been described that inhibits development of EAE and promotes
remyelination following chemically-induced demyelination (Smith
et al., 2014). mAb67-2 is a monoclonal antibody speciﬁc for both soluble
and membrane-associated SEMA4D and cross-reactive on human, pri-
mate, rat and mouse SEMA4D with comparable afﬁnity (between 1
and 5.7 nM, as determined by surface plasmon resonance). The antibody
inhibits interaction between SEMA4D and all of its known receptors,
PlexinB1, PlexinB2, and CD72. In vivo delivery of mAb67-2 should
block signaling cascades initiated by SEMA4D and result in reduced
CNS inﬂammation, increased neuronal outgrowth and increased oligo-
dendrocyte maturation and process formation. In fact, anti-SEMA4D
treatment has been shown to be beneﬁcial in multiple rodent models
of EAE, leading to increased oligodendrocyte precursor cell survival, mi-
gration and maturation, remyelination, restored blood–brain barrier in-
tegrity, and improved clinical scores (Smith et al., 2014). Considering
the convergent pathogenic pathways of neuroinﬂammatory and neuro-
degenerative diseases (Borjabad and Volsky, 2012; Ehrnhoefer et al.,
2011; Ellwardt and Zipp, 2014; Lassmann, 2011), anti-SEMA4D treat-
ment may have beneﬁts in other indications, including Huntington dis-
ease (HD).
HD is an inherited, fatal neurodegenerative disease resulting from
the pathogenic expansion of a polyglutamine encoding CAG tract in
exon 1 of the huntingtin (HTT) gene to 36 or more repeats (HDCRG,
1993). HD is characterized bymotor and cognitive deﬁcits and psychiat-
ric disturbance with death usually occurring 15–20 years after onset.
There is currently no disease modifying therapy available for HD (Ross
and Tabrizi, 2011). While disease onset, deﬁned as presentation of
motor deﬁcits, typically occurs in mid-life, many features of HD present
years to decades earlier, including immune activation (Bjorkqvist et al.,
2008), striatal atrophy and loss of brain white matter (Tabrizi et al.,
2009). Additionally, a recent study has demonstrated severely reduced
turnover of cells of the neuronal and oligodendrocyte lineage withinthe human HD striatum (Ernst et al., 2014), indicating impairments in
adult striatal neurogenesis and oligodendrogenesis. Transcriptional
dysregulation is an early feature of HD, and a previous study has
found that expression of SEMA4D and its major CNS receptor, Plexin-
B1, are elevated in grade 0–2 HD striatum and cortex, but not cerebel-
lum (Hodges et al., 2006), suggesting that increased SEMA4D signaling
may play a role in HD pathogenesis. With the potential for anti-
inﬂammatory effects, increased neuronal progenitor survival and pro-
cess extension, and increased oligodendrocyte migration and matura-
tion, inhibition of SEMA4D signaling through anti-SEMA4D treatment
represents a novel approach to therapy for HD.
Materials and methods
Mice and treatments
Mice were maintained under a 12-h light:12-h dark cycle in a clean
facility and given free access to food and water. Experiments were
performed with the approval of the animal care committee of the
University of British Columbia. YAC128 and wild-type (WT) littermates
(Slow et al., 2003) were divided into mAb67-2 (α-Sema4D) or isotype
matched mAb 2B8 (Ctrl) IgG treatment groups (35 WT ctrl, 34 WT
α-Sema4D, 35 YAC128 ctrl, 36 YAC128α-Sema4D).Mice received treat-
ments by weekly intraperitoneal (IP) mAb injection beginning at
6 weeks of age. The majority of mice were kept until 12 months of
age, but a small group (9 WT ctrl, 10 WT α-Sema4D, 10 YAC128 ctrl,
11 YAC128 α-Sema4D) was sacriﬁced at 6 months of age to provide in-
terim neuropathological data. Serum was collected at 3, 6, 9, and
12 months of age by saphenous vein blood draw.
Plexin-B2 and GFAP immunohistochemistry
5-μm PFA-ﬁxed, parafﬁn-embedded sections were deparafﬁnized
using xylene baths and rehydrated with graded ethanol baths. Epitope
retrieval was carried out by a 20-min boil with Target Retrieval Solution
(Dako) followed by 30-min cooling. Slides were washed twicewith PBS
containing 0.05% Tween-20 (TPBS), and nonspeciﬁc binding was
blocked by a 20-min incubation with 2.5% normal goat serum in TPBS.
Following a single TPBS wash, slides were incubated for 60 min with
1:1000 rabbit anti-GFAP (1:1000, Millipore) and 3 μg/ml mouse anti-
PlexinB2 (Millipore) in TPBS. Slides were then washed three times
with TPBS and incubated for 30 min with Alexa 488 labeled goat anti-
mouse IgM (1:400, Invitrogen) and Alexa 647 labeled donkey anti-
rabbit IgG (1:400, Invitrogen) in TPBS. Slides were then washed twice
with TPBS and incubated for 10min with 1 μg/ml DAPI in TPBS, washed
oncewith TPBS, and coverslipwasmountedwith ProlongGold Antifade
mountingmedium (Life Technologies). Slideswere imaged at 60×mag-
niﬁcation using an Exi Aqua camera coupled to an Olympus Ix50
microscope.
SEMA4D and Plexin-B1 qRT-PCR
Twelve month old WT and YAC128 mice were killed with an over-
dose of avertin. Brains were removed and microdissected by region
then stored in RNAlater (Ambion). Total RNA was extracted from
mouse cortex or striatum with RNeasy Mini Kit or RNeasy Micro Kit
(Qiagen) and treated with RNase-free DNaseI. First-strand cDNA was
prepared from 1 μg (cortex) or 180 ng (striatum) of total RNA using
SuperScriptIII First-Strand Synthesis System (Invitrogen). About 40 ng
of cDNA was used in a ﬁnal volume of 10 μl with Power SYBR Green
PCR Master Mix (ABI). Comparative Ct Assay was performed using ABI
7500 Fast Real-Time PCR System under default condition. mRNA ex-
pression levels of target genes (SEMA4D S: CTCATCACTGCCCTTGGACT,
SEMA4D AS: ACCCGTTGACATCCTGAAAG, Plexin-B1 S: TCCTCACGCA
GAATGGTTTT, Plexin-B1 AS: AAGGTGCCTCCCTTCCTGTA) were normal-
ized to 18S RIBO for the cortex (18S-Ribo S: GATTAAGTCCCTGCCCTTTG,
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S: AGCCCAGTGTTACCACCAAG, UBC AS: ACCCAAGAACAAGCACAAGG).
Serum analysis
Evaluation ofα-Sema4DmAb67-2 levels in the sera of study animals
was performed through the use of a qualiﬁed sandwich ELISA. The assay
format consists of coating recombinant marmoset SEMA4D as a capture
antigen on a microtiter plate. Serum samples were added to the
plate, incubated, and unbound components removed through a wash
step. Bound mAb67-2 was subsequently detected with a horseradish
peroxidase-conjugated goat anti-mouse IgG1 antibody; addition of
TMB (3,3′,5,5′-tetramethylbenzidine) allowed the complex to be deter-
mined colorimetrically. The concentration ofmAb67-2 present inmurine
test sampleswas calculated by linear regression against a reference stan-
dard prepared inmouse serummatrix. The lower limit of quantitation of
this assay was 9.3 ng/mL while the upper limit was 200 ng/mL. The
minimum required dilution (MRD) for the system was 1:100.
Behavior testing
All behavior experiments were carried out during the animals' dark
phase by a researcher blind to genotype and treatment. Spontaneous al-
ternation was performed under red lighting. All other tests were per-
formed under white lighting.
Rotarod
Two month-old mice were trained on a ﬁxed speed rotarod
(Ugo Basille) over 3 consecutive days during which motor learning
was assessed as in Southwell et al. (2013). For longitudinal rotarod
testing at 2-month intervals from 2 to 12months of age, an accelerating
program from 5 RPM to 40 RPM over 300 s was used. Mice received 3
trials with a 1-h inter-trial interval and the latency to the ﬁrst fall was
recorded. The average of the 3 testing trials was scored.
Climbing
Micewere placed at the bottom end of a closed-topwiremesh cylin-
der (10 × 15 cm) on the tabletop and recorded with a video camera for
5min. The latency to begin climbing (all four feet off the tabletop), num-
ber of climbing events, and the total time spent climbing during the
5-min trial were scored. Micewere tested longitudinally at 2-month in-
tervals from 2 to 12 months of age.
Spontaneous alternation
Four month-old mice were assessed for preference to explore the
novel arm of a T-maze as described in Carroll et al. (2011a). Brieﬂy,
mice were placed at the base of the T and allowed to choose a goal
arm. A barrier was then lowered to prevent exit from the goal arm dur-
ing a 1-min exploration.Micewere then immediately placed at the base
of the T and once again allowed to choose a goal arm.Mice that entered
the previously explored goal arm were given a score of 0, while mice
that entered the novel arm were given a score of 1.
Open ﬁeld exploration and object learning
Anxiety during a 10-min exploration of an open ﬁeld, the preference
for a known object in a novel location, and the preference for a novel
object were evaluated at 6 months of age as previously described in
Southwell et al. (2013). Activity was recorded by a ceiling-mounted
video camera and scored by Ethovision XT 7 animal tracking software
(Noldus Information Technology). For open ﬁeld exploration, activity
was assessed by total distance traveled and mean velocity, and
anxiety-like behavior was assessed by entries into and time spent in
the center of the ﬁeld. For object learning, the percentage of investiga-
tions to the target object (either the one in the novel location or the
unfamiliar one) was computed.Elevated plus maze
Anxiety during a 5-min exploration of an elevated plus maze was
evaluated in mice aged 8 months as in Southwell et al. (2013) using a
ceiling-mounted video camera and Ethovision XT 7. Distance traveled
and average velocity was assessed as a measure of exploratory activity.
Entries into and time spent in the open arms, in addition to head dips off
the edge of the open arms, were scored as a measure of anxiety.Porsolt forced swim test
A modiﬁed Porsolt forced swim test as in Pouladi et al. (2009) was
used to assess depressive-like behaviors inmice at their ﬁnal behavioral
testing point (6 or 12 months). Brieﬂy, mice were placed in individual
cylinders (25 cm tall × 19 cm wide) ﬁlled with room temperature
water (23–25 °C) to a depth of 15 cm for a period of 6 min. The test
sessions were recorded by a ceiling-mounted video camera. Time
spent swimming versus ﬂoating (immobile) in the last 5 min of the
trial was scored as a measure of depressive-like behavior.Neuropathology and immunohistochemistry
All neuropathology and quantitative immunohistochemistry was
performed by researchers blind to genotype and treatment.Tissue preparation
Mice were perfused intracardially and brains prepared as in
(Southwell et al., 2013). Forebrains were then cut by cryostat into
25-μm free-ﬂoating coronal sections. Sections were stored in PBS with
0.08% sodium azide at 4 °C until immunohistochemical processing.Immunohistochemistry
For each antigen evaluated, a series of 25-μmcoronal sections spaced
200 μm apart spanning the striatum was used. Sections were then
incubated for 30 min at RT in 3% H2O2 to deplete endogenous peroxi-
dases, washed and incubated in primary antibody (Mouse anti-NeuN
(neuronal nuclei), 1:1000, Millipore; rat anti- dopamine- and cAMP-
regulated phosphoprotein (DARPP-32), 1:5000, R&D Systems) over-
night at room temperature. Sections were washed and incubated with
biotinylated secondary antibody (1:1000; Vector) for 2 h at room
temperature. Signal was ampliﬁed using the Vectastain ABC kit, and
staining was visualized using metal enhanced DAB (Thermo Scientiﬁc).Quantitation of DARPP-32
Sections were photographed using a Zeiss Axioplan 2 microscope
and Coolsnap HQ Digital CCD camera (Photometrics). The amount of
DARPP-32 was determined using MetaMorph software version 6.3
(Universal Imaging Corporation). Labeling was identiﬁed and back-
ground excluded using threshold levels for all images and analyzed
using “integrated morphometry”. Relative levels of staining were calcu-
lated as the sum of the integrated optical density (IOD) for each image
divided by the area of the region selected then multiplied by the
sampling interval (8) and section thickness (25 μm)(Southwell et al.,
2013). IOD was then normalized to WT Ctrl. No staining was observed
in a negative control without primary antibody.Stereological volumetric assessments
In the NeuN-stained section series, striatal, cortical and corpus
callosum volumes were determined by tracing the perimeter of the
desired structure in serial sections using StereoInvestigator software
(Microbrightﬁeld) and volumes determined using the Cavalieri princi-
ple. The thickness of each layer (I, II/III, IV and V/VI) in the primary
motor or sensory cortex was measured using the StereoInvestigator
software “measure” tool.
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Longitudinal data were analyzed by 2-way analysis of variance
(ANOVA) for age or training day and group and Bonferroni post-hoc
analysis. Single time point data was analyzed by 2-way ANOVA for
genotype and treatment or trial and Bonferroni post-hoc analysis. Re-
sults from ANOVA analysis are presented in Supplementary Table S2
and results from Bonferroni post-hoc analysis are presented on graphs.
On longitudinal graphs, * represents difference from WT Ctrl group
(where post-hoc comparison to WT Ctrl group is not different for
YAC128 Ctrl and YAC128α-Sema4D groups, only 1 signiﬁcance marker
is included). On single time point graphs, * represents difference be-
tween indicated bars, ns = not signiﬁcant, * = p b 0.05, ** = p b 0.01,
***p b 0.001. N for each group is reported on the bars for bar graphs or
in Supplementary Table S3 for line graphs.
Results
Study overview
We employed the YAC128mouse model of HD (Slow et al., 2003) to
assess the preclinical therapeutic efﬁcacy of anti-SEMA4D immunother-
apy for HD. YAC128 andWT littermates receivedweekly IP injections of
mAb67-2 (α-Sema4D) or mAb 2B8 (Ctrl) from 6weeks of age until 6 or
12months of age, andwere evaluated for CNS and peripheral pathology,
longitudinal motor performance, psychiatric behaviors, and cognitive
performance.
The SEMA4D signaling pathway in YAC128 brain
To determine if the SEMA4D signaling pathway is dysregulated in
the YAC128 mouse model of HD as it is in the HD brain, we assessed
the relative expression of SEMA4D and its major CNS receptor, Plexin-
B1, in the striatum and cortex of 12 month-old YAC128 and WT litter-
mates. Similar to previously reported data from HD patient brain
(Hodges et al., 2006), we observed an increase in SEMA4D expression
in the striatum of 12 month old YAC128 mice (Fig. 1A). While Plexin-Fig. 1. The SEMA4D signaling pathway is dysregulated in YAC128 striatum. (A,B) qRT-PCR wa
striatal lysates from 12month-old YAC128 andWTmice. *= p b .05. (C) Sections from 12mont
marker GFAP (red). Composite images with DAPI (blue) to visualize cellular nuclei, are shown i
camera coupled to an Olympus I × 50 microscope.B1 is also elevated in the human HD striatum, we observed a trend
toward decreased expression in YAC128 striatum (Fig. 1C), which
could be the result of compensation for increased SEMA4D expression.
Additionally, while both genes are elevated in HD cortex, we observed
no alterations in cortex of YAC128 mice (data not shown). These differ-
ences between YAC128 brain andhumanHDbrain could be the result of
imperfect concordance of gene expression changes between the two
(Becanovic et al., 2010) or the fact that the YAC128 model is a model
of early disease and many of the HD-like gene expression changes that
are observed in the brains of YAC128 mice are not yet evident at
12months of age (Kuhn et al., 2007).We next performed immunohisto-
chemical analysis of SEMA4Dand one of itsmajor CNS receptors, Plexin-
B2, in striata of 12 month old YAC128 andWTmice. Elevated Plexin-B2
receptor protein was observed on GFAP positive activated astrocytes in
YAC128 brain (Fig. 1C). Combined with the observed striatal gene ex-
pression changes, these data indicate that the SEMA4D signaling path-
way is disrupted in the YAC128 brain, and therefore, that the YAC128
mouse is an appropriatemodel system for evaluation of SEMA4D immu-
notherapy for HD.
Neuropathology
Similar to humanHD, YAC128mice exhibit selective and progressive
loss of striatal, cortical, andwhitematter volumes (Carroll et al., 2011b).
To assess the effect of α-Sema4D treatment on HD-like neuropath-
ological features in YAC128 mice, the post-perfusion brains of 6- or
12-month old YAC128 mice were coronally sectioned and stained for
either NeuN, a marker of all neuronal nuclei, or DARPP-32, a marker of
healthy medium spiny striatal neurons. NeuN-stained sections were
used to assess sub-region atrophy within the brain (Figs. 2, S1, and
S2). At 6 months of age, Ctrl-treated YAC128 mice displayed expected
striatal atrophy (6.4% loss), whichwas ameliorated byα-Sema4D treat-
ment (3.8% loss). However, at this early time point the other neuropath-
ological endpoints assessed revealed only trends toward genotypic
differences, precluding a full assessment of the effects of anti-SEMA4D
immunotherapy (Fig. S2). At 12 months of age, Ctrl-treated YAC128
mice displayed a broad range of neuropathological features, includings used to measure the relative gene expression level of (A) SEMA4D and (B) Plexin-B1 in
h old YAC128 andWT brain were co-stained for plexin-B2 (PlexinB2, green) and astrocyte
n the left-most panels. Slides were imaged at 60×magniﬁcation using an EXi-Aqua-14 bit
Fig. 2.Anti-SEMA4D treatment preserves brain gray andwhitematter. Neuropathologywas evaluated at 12months of age by (A) forebrainweight, (B) striatal volume, (C) cortical volume,
(D) corpus callosum volume, and (E, F) cortical layer thickness in primary motor cortex. ns = not signiﬁcant, * = p b .05, ** = p b .01.
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and 8.7% cortical volume loss (Fig. 2B, C). An 8.8% reduction of corpus
callosum volume, indicating loss of brain white matter, was also
observed (Fig. 2D). Ctrl-treated YAC128 mice also displayed layer-
speciﬁc thinning of primary motor cortex (Fig. 2E, F). Consistent with
previous reports (Carroll et al., 2011b), there was no effect of genotype
noted on cortical layer thickness in layers I or IV of primarymotor cortex
or in any layer of primary sensory cortex, and we observed no effect
of α-Sema4D treatment in these regions (data not shown). α-Sema4D
treatment ameliorated forebrain weight (4.3% loss), striatal vol-
ume (5.1% loss), cortical volume (2.9% loss), corpus callosum volume
(3.8% loss), and thinning of cortical layers II/III and V/VI in YAC128
mice compared to Ctrl-treated YAC128 mice, indicating mAb-
mediated inhibition of SEMA4D is broadly neuroprotective and capable
of preserving both brain gray and white matter in the context of ongo-
ing HD pathogenesis.
The integrated optical density (IOD) of DARPP-32 immunoreactivity
was measured in a set of sections spaced 200 μM apart spanning thestriatum. The IOD for each mouse was then normalized to the mean
value for the WT Ctrl group from the same cohort. Ctrl-treated YAC128
mice displayed a trend toward reduced DARPP-32 immunoreactivity at
6 months of age and a signiﬁcant 21.4% reduction at 12 months of age.
This was improved by α-Sema4D treatment to a 5.6% reduction, a level
that is not signiﬁcantly different from α-Sema4D treated WT mice
(Fig. 3). These treatment-speciﬁc volumetric changes, in aggregate, sug-
gest inhibition of SEMA4D signaling impedes regional brain degenera-
tion that progressively develops in the YAC128 HD mouse model.
Peripheral pathology
Levels of huntingtin are highest in the brain and testes (Strong
et al., 1993), and while fertility is generally unaffected (Pridmore
and Adams, 1991), men with HD exhibit reduced testosterone con-
centrations as well as marked testicular degeneration (Markianos
et al., 2005; Van Raamsdonk et al., 2007). Consistent with previous
reports (Van Raamsdonk et al., 2006; Van Raamsdonk et al., 2005),
Fig. 3. Anti-SEMA4D treatment preserves striatal DARPP-32 expression. To evaluate health of striatal medium spiny neurons, DARPP-32 immunoreactivity was quantiﬁed at 6 and
12 months of age. (A) Representative images from 12 month-old animals. (B) Total integrated optical density normalized to mean WT Ctrl values from the same cohort. *** = p b .001.
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niﬁcantly smaller than those of Ctrl-treated WT mice, indicating tes-
ticular degeneration. This degeneration was completely prevented
by α-Sema4D treatment, as testis weights were indistinguishable
between WT and α-Sema4D treated YAC128 male mice (Fig. 4).Fig. 4. Anti-SEMA4D treatment prevents testicular degeneration in YAC128 mice. Testis
weight was assessed in post-perfusion 12 month-old male mice. Ctrl-treated YAC128
mice had smaller testis than WT mice, indicating testicular degeneration. Conversely,
there was no loss of testis weight observed in α-Sema4D treated YAC128 mice, demon-
strating rescue of the testicular degeneration phenotype. * = p b .05.Another peripheral abnormality reported to affect nearly all individ-
uals with HD and some other HD transgenic models, and which is not
necessarily associated with pathology of the CNS, is progressive weight
loss due to purported effects of muHTT expression on the digestive
system and adipocyte function (Aziz et al., 2008; Phan et al., 2009).
Conversely, full-length human HTT transgenic mousemodels, including
the YAC128, exhibit signiﬁcant weight gain (Gray et al., 2008; Slow
et al., 2003). This weight gain is modulated by levels of transgenic HTT
(Van Raamsdonk et al., 2006), which is indicative of HTT-associated
metabolic abnormalities, despite the inverse phenotype. Body weight
of α-Sema4D or Ctrl-treated YAC128 and WT mice was compared at
2-month intervals from 2 to 12 months of age (Fig. S3). As expected,
Ctrl-treated YAC128 mice, especially females, displayed an increase in
body weight compared to Ctrl-treated WT mice. α-Sema4D treatment
had no effect on the body weight of YAC128 mice.
Evaluation of α-Sema4D mAb67-2 levels in longitudinal serum
mAb67-2 concentration was measured in pooled sera at 3, 6, 9, and
12 months of age for all groups (Table S1). Sera from mAb67-2 treated
animals contained expected levels of drug consistent with previous
studies (Smith et al., 2014). However, mAb67-2 was also detected at
much lower levels (25 to 25,000-fold less) in sera from both Ctrl-
treated groups. When sera from each animal were evaluated
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detectable in nearly all the animals. Due to the global nature, this is like-
ly the result of cross-contamination. α-Sema4D and Ctrl-treated ani-
mals were inter-housed during the study in order to ensure that the
researchers performing the experiments remained blind to the treat-
ment, and to eliminate any potential housing bias within the data.
Inter-housed animals are in continual close contact and groom one an-
other. If mAb67-2 leaks following IP immunization or is excreted from
recipient animals in an active, non-metabolized form, and is cutaneous-
ly or orally bioavailable, inter-housing could result in low levels of drug
in the Ctrl-treated cagemates ofα-Sema4D treated animals. Despite the
low levels of mAb67-2 detected in Ctrl-treated groups, the expected
pathologic differences between Ctrl-treated YAC128 and WT mice
were readily observed, indicating that the very low level of drug in
these animals was below the threshold of activity.Motor performance
To determine if anti-SEMA4D immunotherapy could alleviate the
knownmotor deﬁcits of YAC128mice, treatedmice underwent longitu-
dinal rotarod and climbing testing (Fig. 5). Compared to Ctrl-treatedWT
mice, Ctrl-treated YAC128 mice displayed expected deﬁcits, showing a
progressive decline in rotarod performance and time spent climbing.
Ctrl-treated YAC128mice fell from the accelerating rotarod signiﬁcantly
sooner than WT mice from 4 months of age and onward. α-Sema4D
treated YAC128 mice were not signiﬁcantly different from Ctrl-treated
WT mice until 6 months of age. However, they too exhibited declining
rotarod performance that was indistinguishable from Ctrl-treated
YAC128 mice (Fig. 5A). Both Ctrl and α-Sema4D treated YAC128
mice displayed progressive deﬁcits in spontaneous climbing with an
increased latency to begin climbing, decreased number of climbing
events, and decreased time spent climbing as compared to Ctrl-treated
WT mice (Fig. 5B–D). Taken together, these data indicate that anti-Fig. 5. Anti-SEMA4D treatment has no effect on motor deﬁcits of YAC128 mice. Mice were as
climbing (B–D) at 2 month intervals from 2 to 12 months of age. ns = not signiﬁcant, * = p bSEMA4D immunotherapy does not improve motor performance of
YAC128 mice.
Cognitive performance
Prior to clinical diagnosis, individuals with HD begin to manifest
modest cognitive deﬁcits that primarily relate to erosion of procedural
memory (the ability to learn and recall newmotor skills) and visuospa-
tialmemory recall (Butters et al., 1985). To assess the effects of SEMA4D
inhibition on cognitive function in YAC128 mice, mice were evaluated
for motor learning during rotarod training at 2 months of age, for
spontaneous alternation during exploration of a T maze at 4 months of
age, and for object location and recognition learning at 6 months of
age (Figs. 6 and S4). While both Ctrl and α-Sema4D treated YAC128
mice displayed increased falls and decreased latency to fall from the
rotarod on day 1 of training, there was a trend toward reduced falls in
the α-Sema4D treated group. On day 2 of training and on the test day,
Ctrl-treated YAC128 mice displayed decreased latency to fall compared
to Ctrl-treated WT mice, while at these time points, α-Sema4D treated
YAC128 mice were not signiﬁcantly different from WT Ctrl mice
(Fig. 6A,B), indicating improved motor learning in α-Sema4D treated
YAC128mice. In another cognitive paradigm,α-Sema4D treatment res-
cued the object learning deﬁcits of YAC128 mice. Ctrl and α-Sema4D
treated WT mice displayed a preference for investigating a known ob-
ject in a novel location, while Ctrl-treated YAC128 mice displayed no
preference; investigating both the object in the original location and
the object in the novel location equally. α-Sema4D treatment restored
the preference for an object in a novel location in YAC128 mice
(Fig. 5C), indicating a rescue of spatial learning deﬁcits. In addition,
both groups of WT mice displayed a preference for investigating a
novel object over a known object, while Ctrl-treated YAC128 mice
displayed no preference; investigating both the novel and known ob-
jects equally. α-Sema4D treatment restored the preference for a novel
object in YAC128mice, indicating a rescue of object recognition deﬁcits.sessed for motor performance by longitudinal accelerating rotarod (A) and spontaneous
.05, ** = p b .01, *** = p b .001.
Fig. 6.Anti-SEMA4D treatment improves cognitive performance of YAC128mice.Motor learningwas evaluated at 2months of age during three consecutive days of rotarod training (A, B).
Spatial learning and object recognition were evaluated at 6 months of age by novel object location and novel object preference test, respectively (C, D). * = p b .05, ** = p b .01, *** =
p b .001.
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ous alternation deﬁcit of YAC128mice. Both Ctrl-treated andα-Sema4D
treated YAC128 mice performed at roughly the level of chance in thisFig. 7. Anti-SEMA4D treatment ameliorates anxiety-like behavior of YAC128 mice. To evaluate
Sema4D treated mice were evaluated for time spent in the center of an open ﬁeld under brig
and for entries into the open arms and head dips off the side of the open arms of an elevated
and for immobility during the last 5 minutes of a 6 minute forced swim at 12 months of age asassay, entering the previously explored and unexplored arms of the
maze with equal frequency, while both WT groups preferentially en-
tered the unexplored arm of the maze (Fig. S4).the effect of antibody-mediated SEMA4D blockade on psychiatric behaviors, Ctrl and α-
ht lighting during a 10-min exploration at 6 months of age as a measure of anxiety (A),
plus maze during a 5-min exploration at 8 months of age as a measure of anxiety (B, C),
a measure of depressive behavior (D). ns = not signiﬁcant, * = p b .05, ** = p b .01.
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Depression, irritability, and impulsivity are the most common
psychiatric features exhibited by HD-afﬂicted individuals (Duff et al.,
2007). These psychiatric behaviors typically present prior to full disease
onset and negatively impact overall quality of life. To evaluate the effect
of anti-SEMA4D immunotherapy on psychiatric-like phenotypes of
YAC128 mice, treated mice were assessed at 6 months of age during
open ﬁeld exploration, at 8 months of age during elevated plus maze
exploration, and at 12 months of age using a modiﬁed Porsolt forced
swim test (Fig. 7). As compared to Ctrl-treated WT mice, Ctrl-treated
YAC128 mice displayed expected anxiety-like phenotypes, spending
signiﬁcantly less time in the center of the open ﬁeld and less frequently
entering into or dipping their heads off of the edge of the open arms
of the elevated plus maze. While no signiﬁcant effects of α-Sema4D
treatment were observed in these measures, treatment did induce a
trend toward increased center time, open arm entries, and head
dips in YAC128 mice resulting in no signiﬁcant differences between
α-Sema4D treated WT and YAC128 mice (Fig. 7A–C), suggesting a
beneﬁt to anxiety-like behavior. No effects of genotype or treatment
were observed on distance traveled ormeanvelocity during exploration
of the open ﬁeld or the elevated plus maze (Fig. S5), indicating that
the differences observed in anxiety-like behavior were not the result
of altered spontaneous exploratory activity. In a separate test of
depressive-like behavior, Ctrl-treated YAC128 mice spent signiﬁcantly
more time immobile and less time swimming than Ctrl-treated WT
mice during forced swimming. However, while no signiﬁcant difference
in depressive-like behavior was observed between α-Sema4D treated
WT and YAC128 mice by 2-way-ANOVA, the genotypic difference
remained quite large in treated mice, and a binary t-test of only the
α-Sema4D treated groups was signiﬁcant (p = 0.0125), suggesting
that depressive-like behavior persists in these animals.
Discussion
Anti-semaphorin 4D immunotherapy provided signiﬁcant beneﬁt
to the HD-like neuropathological and behavioral phenotypes of the
YAC128 transgenic mouse model of HD. In many cases the effect of
α-Sema4D treatment was greater in YAC128 than in WT mice or only
apparent in YAC128 mice, indicating modiﬁcation of HD-related patho-
genic processes. In particular, SEMA4D blockade improved several
HD-related pathologies including testicular degeneration and striatal,
cortical, and corpus callosum volume loss as well as improving a subset
of learning deﬁcits and anxiety-like behavior.
α-Sema4D treatment signiﬁcantly increased corpus callosum
volume in both genotypes. This is consistent with previous reports
that SEMA4D inhibition increases proliferation, maturation, and
migration oligodendrocyte precursor cells (Smith et al., 2014). The in-
crease in corpus callosum volume following α-Sema4D treatment was
more pronounced in YAC128 than WT mice and resulted in ameliora-
tion of the atrophy phenotype. Additionally, in all stereological mea-
surements evaluated there were no signiﬁcant differences observed
between anti-SEMA4D treated WT and YAC128 animals while in most
instances signiﬁcant differences were observed between Ctrl-treated
WT and YAC128 animals. The striking lack of difference between the
α-Sema4D treatedWT and YAC128 groups in these broadmeasures in-
dicates that anti-SEMA4D treatment promotes preservation of both
brain gray and white matter, outcomes with profound therapeutic
potential.
Anti-SEMA4D immunotherapy fully rescued testicular degeneration
in YAC128 males. The HTT protein is expressed ubiquitously, however,
expression is by far the highest in the brain and testes (Sharp et al.,
1995). The mechanisms leading to testicular degeneration in HD are
thought to include intrinsic apoptotic death of spermatogenic and
Sertoli cells mediated by muHTT (Leavitt et al., 2001). SEMA4D is
expressed in the testes (Hall et al., 1996), and our data indicate that itmay play a role in muHTT-induced testicular cell death similar to its
role in death of immature neurons and oligodendrocytes in the brain.
In fact, there is signiﬁcant similarity in the role of SEMA4D in actin net-
works and vesicle transport in the nervous system (Kuzirian et al.,
2013), and theHTT protein,which, in oneof itsmany roles, is a cytoskel-
etal scaffold that mediates vesicular and molecular transport (Caviston
and Holzbaur, 2009; Caviston et al., 2011). The muHTT protein perturbs
this process, potentially leading to initiation of SEMA4D-mediated cyto-
skeletal breakdown and subsequent apoptosis,whichmay be prevented
by anti-SEMA4D mAb-based treatment.
Anti-SEMA4D immunotherapy did not provide beneﬁt to the motor
deﬁcits in YAC128mice. However, HD patients commonly report that it
is the cognitive and psychiatric aspects of the disease that most nega-
tively impact their quality of life (Adam and Jankovic, 2008), and
these aspects of the YAC128 HD-like phenotype were improved by
SEMA4D blockade. Beneﬁts to psychiatric aspects were apparent in
amelioration of anxiety-like behavior in both the open ﬁeld and elevat-
ed plus maze exploration tasks. The effect of α-Sema4D administration
on cognitive performance was mixed. A small improvement to motor
learning during rotarod training was observed at two months of age. It
is possible that treatment related changes would increase with age,
however, as motor deﬁcits were not improved, a full rescue of the
motor learning deﬁcit might not be expected even given a complete re-
covery of cognitive performance. There was no effect of α-Sema4D on
the spontaneous alternation deﬁcit of YAC128 mice, indicating that
treated mice still had spatial learning deﬁcits. However, anti-SEMA4D
treatment resulted in a full rescue of object location spatial learning.
As the spontaneous alternation task is carried out in a completely sym-
metrical and unmarked T maze, it is likely a more difﬁcult spatial dis-
crimination task than the object location task, which is asymmetrical
(Southwell et al., 2009). Supporting this is the ﬁnding that spontaneous
alternation deﬁcits are apparent in YAC128 mice prior to the onset of
object location learning deﬁcits (unpublished observation). The differ-
ential difﬁculty of these two tasks could account for rescue being ob-
served in one paradigm but not the other. α-Sema4D administration
also resulted in a complete rescue of the object recognition deﬁcits of
YAC128 mice. Taken together, these data indicate that the psychiatric
and cognitive aspects of theHD-like phenotypes of YAC128mice are im-
proved, but not abolished by anti-SEMA4D mAb treatment.
Striatal medium spiny neurons (MSNs) play a pivotal role in motor
control (reviewed by Graybiel et al., 1994). MSNs receive signiﬁcant
dopaminergic and glutamatergic input via the substantia nigra pars
compacta and cortex, respectively, and their function and viability
are believed to be especially susceptible in the setting of HD due
to multiple intrinsic and extrinsic mechanisms (reviewed by Ehrlich,
2012). Intrinsic processes that have been shown to underlie HD-
related MSN dysfunction and eventual demise include abnormal aggre-
gation and clearance of polyQ-htt, mitochondrial dysfunction, dimin-
ished neurotrophin levels, transcriptional dysregulation, disruption of
axonal transport, and excitotoxicity, while extrinsic mechanisms
include astrocyte and oligodendrocyte dysfunction, microglial activa-
tion, and abnormal cortical neuron function (Ehrlich, 2012; Zuccato
et al., 2010). While striatal volume (Fig. 1) and DARPP-32 expression
(Fig. 2) within the striatum were relatively preserved by anti-SEMA4D
treatment, the inability of anti-SEMA4D immunotherapy to improve
motor function in YAC128micemay reﬂect persistent functional deﬁcits
related to the inherent susceptibility of MSNs to intrinsic pathogenic
mechanisms, which represent cellular processes that currently are not
known to be overtly regulated by SEMA4D-Plexin signaling.
The blood–brain barrier (BBB) in the setting of HD pathogenesis is
not generally thought to be signiﬁcantly compromised, especially
when compared to the highly damaged neurovascular unit in other
neuroinﬂammatory/neurodegenerative diseases, such as MS and AD
(reviewed by Neuwelt et al., 2011). For example, comparison of BBB
permeability values between the aggressive R6/2 model of HD and
wild-type littermates revealed no signiﬁcant differences (Cepeda-
55A.L. Southwell et al. / Neurobiology of Disease 76 (2015) 46–56Prado et al., 2012). Interestingly, however, Lin et al. recently reported
that R6/2 mice as well as humans with HD exhibit detectable enhance-
ments in microvasculature densities (Lin et al., 2013), and progressive
neurovascular abnormalities have previously been reported in YAC128
mice (Franciosi et al., 2012), which suggests some degree of disease-
related dysfunction in the HD neurovascular unit. As reported else-
where, SEMA4D blocking antibody preserves the integrity of the BBB
under inﬂammatory conditions by preventing downregulation of
Claudin-5 and breakdown of endothelial tight junctions (Smith et al.,
2014). It is possible that this also contributes to therapeutic beneﬁt in
HD.
Despite the pleiotropic effects of treatment with anti-SEMA4D
antibody, modulating BBB integrity, promoting neuronal process
extension, and oligodendrocyte differentiation/viability, we did not
observe any drug-related side effects/toxicities of anti-SEMA4D anti-
body in this study. Moreover, single and 6 month repeat-dose toxicity,
pharmacokinetic, and pharmacodynamic studies with a humanized,
mAb67-2-derived anti-SEMA4D IgG4 antibody (VX15/2503) have
been completed in cynomolgus monkeys and rats at doses up to
200 mg/kg with no toxicity observed (manuscript in preparation).
VX15/2503 has completed a Phase I clinical trial in patients with solid
tumors (clinicaltrials.gov identiﬁer: NCT01313065) and is currently
enrolling patients in the highest dose cohort of a phase 1 trial in patients
with multiple sclerosis (clinical trials.gov identiﬁer: NCT01764737) in
support of safety and tolerability of VX15/2503 in these patient popula-
tions. Given its highly relevant mechanisms of action, with further
validation, and possibly in combination with other drug(s), such as
tetrabenazine, which can moderate motor symptoms (Group, 2006),
mAb-based SEMA4D inhibition could serve as a much needed disease-
modifying therapy for HD.
Additionally this work further demonstrates the similarity of path-
ogenic mechanisms in neuroinﬂammatory and neurodegenerative
diseases and provides rationale for the re-purposing of therapeutics
developed for other such indications in the treatment of HD.
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